Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,738 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Failure Chronic Clear all
Completed No phase listed Observational Accepts healthy volunteers

Testing Tissue Sodium Stores in CAPD Patients-Aims 1 & 2

NCT02212327
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 25, 2026, 3:01 PM EDT
Withdrawn No phase listed Observational

Safety and Efficacy of Apixaban in Severe Renal Impairment

NCT03399305
View directory record Official record
Conditions
Renal Disease, End Stage, Anticoagulant-induced Bleeding
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 25, 2026, 3:01 PM EDT
Terminated Phase 2 Interventional

Complementary Intradialytic Nutritional Supplementation in Dialysis Patients

NCT00179205
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Nepro nutritional supplement, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Patiromer in Heart Failure Patients

NCT00868439
View directory record Official record
Conditions
Hyperkalemia, Heart Failure
Interventions
patiromer, placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Miami, Florida • Port Charlotte, Florida • Peoria, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 25, 2026, 3:01 PM EDT
Completed No phase listed Observational

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

NCT04566653
View directory record Official record
Conditions
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
Interventions
Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water, Veltassa® 8,4 g/80mL water, Sodium Polystyrene Sulphonate 15g/60 mL water
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Temple Terrace, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

NCT03000673
View directory record Official record
Conditions
Antithrombotic
Interventions
Enoxaparin, unfractionated heparin (UFH), BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 25, 2026, 3:01 PM EDT
Not yet recruiting No phase listed Observational

Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring

NCT07880795
View directory record Official record
Conditions
End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
Interventions
Continuous Glucose Monitoring (CGM)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D Repletion in Chronic Kidney Disease

NCT00772772
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vitamin D3
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 25, 2026, 3:01 PM EDT
Enrolling by invitation No phase listed Observational

Renal Allograft Fibrosis Study

NCT05058170
View directory record Official record
Conditions
Renal Allograft Fibrosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 25, 2026, 3:01 PM EDT
Withdrawn Phase 4 Interventional

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

NCT03073369
View directory record Official record
Conditions
CKD, Chronic Kidney Diseases, Hepcidin, Ergocalciferol, Vitamin D, Iron-deficiency, Anemia
Interventions
Ergocalciferol 50000 UNT, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Not applicable Interventional Results available

Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate

NCT00962000
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Renal Disease
Interventions
Dialysis Flow Rate Start 600mL/min, Dialysis Flow Rate Start 800mL/min
Other
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Sacramento, California • Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Phase 3 Interventional

SAfety of Regional Citrate Anticoagulation (SARCA Study)

NCT05339139
View directory record Official record
Conditions
Acute Kidney Injury, ESRD
Interventions
Dialysis
Combination Product
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Orlando, Florida • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Not applicable Interventional

Renal Effects of Melatonin Trial in Chronic Kidney Disease

NCT04336566
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Melatonin, Placebo
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 25, 2026, 3:01 PM EDT
Not listed No phase listed Observational

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

NCT05214105
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Diseases, Chronic
Interventions
Biospecimen/DNA collection and analysis
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Winston-Salem, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 25, 2026, 3:01 PM EDT
Not listed Phase 2 Interventional

Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

NCT00358046
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency
Interventions
ILY101
Drug
Lead sponsor
Ilypsa
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Mountain View, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Not applicable Interventional

Remote Physician Care for Home Hospital Patients

NCT04080570
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Remote Visit
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 25, 2026, 3:01 PM EDT
Recruiting Not applicable Interventional

Enhancing Physical Function in Older Adults With Chronic Kidney Disease

NCT06738394
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
High-Velocity Resistance Training, Attention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 3:01 PM EDT
Completed No phase listed Observational

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

NCT04818151
View directory record Official record
Conditions
Venous Thromboembolic Disease, Kidney Failure, Chronic
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Phase 2Phase 3 Interventional

Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease

NCT01180101
View directory record Official record
Conditions
Chronic Kidney Disease, Obesity
Interventions
Diet and exercise, Bariatric Surgery
Behavioral · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
19 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 25, 2026, 3:01 PM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

NCT06858319
View directory record Official record
Conditions
Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Interventions
zigakibart
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
8
States / cities
Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598442
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 25, 2026, 3:01 PM EDT
Completed Phase 4 Interventional Results available

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

NCT03781089
View directory record Official record
Conditions
Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer Oral Powder Product
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 25, 2026, 3:01 PM EDT
Recruiting No phase listed Observational

The KidneyCARE (Community Access to Research Equity) Study

NCT05497518
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Kidney Transplant
Interventions
Observational study - registry
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2070
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 25, 2026, 3:01 PM EDT